Humacyte, Inc. logo

Humacyte, Inc. (HUMA)

Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
1. 4000
+0.01
+0.72%
$
193.2M Market Cap
- P/E Ratio
- Div Yield
5,479,378 Volume
-0.9 Eps
$ 1.39
Previous Close
Add Transaction
Day Range
1.35 1.46
Year Range
0.547 2.93
Want to track HUMA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.62, indicating a -4.14% shift from the previous trading day.

Zacks | 7 months ago
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

Humacyte, Inc. (HUMA) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day.

Zacks | 7 months ago
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors

Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.79, representing a +1.7% change from its previous close.

Zacks | 7 months ago
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks | 9 months ago
Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.

Seekingalpha | 9 months ago
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.27 per share a year ago.

Zacks | 9 months ago
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.21, signifying a -4.33% move from its prior day's close.

Zacks | 10 months ago
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.

Zacks | 10 months ago
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.

Zacks | 10 months ago
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.

Zacks | 10 months ago
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today

Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today

Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.

Zacks | 10 months ago
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.

Zacks | 10 months ago
Loading...
Load More